Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Antidepressant
Seltorexant
Другие языки:

    Seltorexant

    Подписчиков: 0, рейтинг: 0
    Seltorexant
    MIN-202.svg
    Clinical data
    Other names MIN-202; JNJ-42847922; JNJ-922
    Routes of
    administration    		 By mouth
    Drug class Orexin antagonist
    ATC code
    • None
    Legal status
    Legal status
    Pharmacokinetic data
    Metabolism CYP3A4
    Elimination half-life 2–3 hours
    Identifiers
    • [5-(4,6-Dimethylpyrimidin-2-yl)-hexahydropyrrolo[3,4-c]pyrrol-2-yl]-(2-fluoro-6-[1,2,3]triazol-2-ylphenyl)methanone
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    KEGG
    Chemical and physical data
    Formula C21H22FN7O
    Molar mass 407.453 g·mol−1
    3D model (JSmol)
    • c4c(C)nc(nc4C)N5CC2CN(CC2C5)C(=O)c1c(cccc1F)-n3nccn3
    • InChI=1S/C21H22FN7O/c1-13-8-14(2)26-21(25-13)28-11-15-9-27(10-16(15)12-28)20(30)19-17(22)4-3-5-18(19)29-23-6-7-24-29/h3-8,15-16H,9-12H2,1-2H3/t15-,16+
    • Key:SQOCEMCKYDVLMM-IYBDPMFKSA-N

    Seltorexant, also known by its developmental code names MIN-202 and JNJ-42847922, is an orexin antagonist medication which is under development for the treatment of depression and insomnia. It is a selective antagonist of the orexin OX2 receptor (2-SORA). The medication is taken by mouth. As of February 2022, seltorexant is in phase 3 clinical trials for treatment of major depressive disorder (MDD) and phase 2 trials for treatment of insomnia. It was also under investigation for the treatment of sleep apnea, but no recent development has been reported for this indication. Seltorexant is under development by Minerva Neurosciences and Johnson & Johnson's Janssen Pharmaceuticals.

    Seltorexant is being explored at doses of 5 to 80 mg. In the early clinical trials conducted so far, seltorexant has been found to improve depression scores on the Hamilton Depression Rating Scale in people with MDD and to improve sleep onset, total sleep time, time awake after sleep onset, and sleep efficiency in people with MDD and/or insomnia. Seltorexant is reported to be safe and well-tolerated.Side effects of seltorexant observed in clinical trials so far have included somnolence, fatigue, dizziness, headache, abdominal discomfort, and nightmares.

    Seltorexant shows over 100-fold greater binding affinity for the OX2 receptor over the OX1 receptor. This is in contrast to other orexin receptor antagonists like suvorexant, lemborexant, and daridorexant, which are all dual orexin receptor antagonists (DORAs). Seltorexant has fast absorption with a time to peak levels of 0.3 to 1.5 hours and has a relatively short duration with an elimination half-life of only 2 to 3 hours. No residual effects of the medication were observed 4 hours after daytime administration. The pharmacokinetics of seltorexant are considered to be ideal for sleep induction. Seltorexant is metabolized by the cytochrome P450 enzyme CYP3A4. It is a small-molecule compound and is structurally related to other clinically used orexin receptor antagonists.

    See also

    External links


    Новое сообщение